Search results

...g the duration of anticoagulation, see [[embolism and thrombosis#treatment|embolism and thrombosis: treatment]]. [[Clinical practice guideline]]s address the management of severe forms of [[embolism and thrombosis]] which may require [[thrombolysis]].<ref name="pmid21422387">{{cite jour

* score 0 is low risk. 0.8% rate of [[embolism and thrombosis]] at one year * score 1 is intermediate risk. 2.0% rate of [[embolism and thrombosis]] at one year

...of the [[arm]] are affected (known as ''[[Paget-Schrötter disease]]''). [[Embolism and thrombosis]] is the more general class of pathologies of this kind. ! Wells score !! Death (%) from [[embolism and thrombosis]] ([[Confidence interval|95% CI]])

...-02-19}}</ref> Concomittent use of [[warfarin]] may be needed to prevent [[embolism and thrombosis]].

...oagulant]] medication used prophylactically to suppress the formation of [[embolism and thrombosis]] from conditions such as [[atrial fibrillation]], [[deep venous thrombosis

[[Rosuvastatin]] may also prevent venous [[embolism and thrombosis]].<ref name="pmid19329822">{{cite journal| author=Glynn RJ, Danielson E, Fo

...g erythropoiesis-stimulating agents in patients with cancer may increase [[embolism and thrombosis]] and mortality.<ref>Bennett, C. L., Silver, S. M., Djulbegovic, B., Samara